Abstract:Targeting tumor vasculature represents an intriguing therapeutic strategy in the treatment of cancer. In an effort to discover new vascular disrupting agents with improved water solubility and potentially greater bioavailability, various amino acid prodrug conjugates (AAPCs) of potent amino combretastatin, amino dihydronaphthalene, and amino benzosuberene analogs were synthesized along with their corresponding water-soluble hydrochloride salts. These compounds were evaluated for their ability to inhibit tubulin polymerization and for their cytotoxicity against selected human cancer cell lines. The amino-based parent anticancer agents 7, 8, 32 (also referred to as KGP05) and 33 (also referred to as KGP156) demonstrated potent cytotoxicity (GI50=0.11–40nM) across all evaluated cell lines, and they were strong inhibitors of tubulin polymerization (IC50=0.62–1.5μM). The various prodrug conjugates and their corresponding salts were investigated for cleavage by the enzyme leucine aminopeptidase (LAP). Four of the glycine water-soluble AAPCs (16, 18, 44 and 45) showed quantitative cleavage by LAP, resulting in the release of the highly cytotoxic parent drug, whereas partial cleavage (<10–90%) was observed for other prodrugs (15, 17, 24, 38 and 39). Eight of the nineteen AAPCs (13–16, 42–45) showed significant cytotoxicity against selected human cancer cell lines. The previously reported CA1-diamine analog and its corresponding hydrochloride salt (8 and 10, respectively) caused extensive disruption (at a concentration of 1.0μM) of human umbilical vein endothelial cells growing in a two-dimensional tubular network on matrigel. In addition, compound 10 exhibited pronounced reduction in bioluminescence (greater than 95% compared to saline control) in a tumor bearing (MDA-MB-231-luc) SCID mouse model 2h post treatment (80mg/kg), with similar results observed upon treatment (15mg/kg) with the glycine amino-dihydronaphthalene AAPC (compound 44). Collectively, these results support the further pre-clinical development of the most active members of this structurally diverse collection of water-soluble prodrugs as promising anticancer agents functioning through a mechanism involving vascular disruption.

Discovery of a potent microtubule-targeting agent: Synthesis and biological evaluation of water-soluble amino acid prodrug of combretastatin A-4 derivatives.

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents

Design and Synthesis of Cyclopropylamide Analogues of Combretastatin-A4 As Novel Microtubule-Stabilizing Agents

Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents

Design, Synthesis, Biological Evaluation and Cocrystal Structures with Tubulin of Chiral Β-Lactam Bridged Combretastatin A-4 Analogues As Potent Antitumor Agents.

Design, concise synthesis and evaluation of novel amide-based combretastatin A-4 analogues as potent tubulin inhibitors

Novel Combretastatin A-4 Analogs—Design, Synthesis, and Antiproliferative and Anti-Tubulin Activity

Design, Synthesis, and Biological Evaluation of Water-Soluble Amino Acid Prodrug Conjugates Derived from Combretastatin, Dihydronaphthalene, and Benzosuberene-Based Parent Vascular Disrupting Agents.

Identification of Novel 1-Indolyl Acetate-5-nitroimidazole Derivatives of Combretastatin A-4 As Potential Tubulin Polymerization Inhibitors.

Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility

Synthesis and Evaluation of 1,5-Disubstituted Tetrazoles As Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative and Antitumor Activity

Design, synthesis of combretastatin A-4 piperazine derivatives as potential antitumor agents by inhibiting tubulin polymerization and inducing autophagy in HCT116 cells

Synthesis and Biological Evaluation of Diarylthiazole Derivatives As Antimitotic and Antivascular Agents with Potent Antitumor Activity.

Design, synthesis, and anti-breast tumor activity of novel combretastatin A-4 analogues

Discovery of Novel 4-Arylisochromenes As Anticancer Agents Inhibiting Tubulin Polymerization.

Design, Synthesis and Characterization of Potent Microtubule Inhibitors with Dual Anti-Proliferative and Anti-Angiogenic Activities

Synthesis and Biological Evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines As a New Class of Tubulin Polymerization Inhibitors.

Design, Synthesis, and Anti-tumor Activity of Novel 2-Aryl Benzimidazole Compounds.

Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.

4,5-Diaryl-3h-1,2-dithiole-3-thiones and Related Compounds As Combretastatin A-4/oltipraz Hybrids: Synthesis, Molecular Modelling and Evaluation As Antiproliferative Agents and Inhibitors of Tubulin